Fitch Ratings backs J&J move to sell Ortho Clinical Dx arm; Covidien declares quarterly cash dividend;

@FierceMedDev: Boston Scientific won't begin its U.S. hypertension study until it reviews Medtronic's setback. More | Follow @FierceMedDev

@MarkHFierce: Google is developing a contact lens that monitors glucose levels. Partners needed to bring the product to market. Story | Follow @MarkHFierce

@MichaelGFierce: Study: Carotid stents, regardless of origin, are similarly effective at preventing stroke, death. Item | Follow @MichaelGFierce

@EmilyWFierce: Flu season predictions from scientists at Columbia could help you stay out of bed. Article | Follow @EmilyWFierce

@GalenMoore: Here's who was in the room when a team from Google X met with FDA officials last month. | Follow @GalenMoore

> Fitch Ratings said it supported plans by Johnson & Johnson ($JNJ) to sell its Ortho Clinical Diagnostics arm to Carlyle Group for $4.15B, calling it a "strategically sound" move to unload a division with lower opportunities for long-term growth. Item

> Sweden's Aerocrine inked an exclusive deal with Healthcare 21 to sell, market and distribute Aerocrine's new airway inflammation monitor and test kit across the U.K. and Ireland. Item

> Covidien ($COV) has declared a quarterly cash dividend of 32 cents per share. Item

> Sequenom ($SQNM) said that France's Nicox will have exclusive rights to market its RenaGene laboratory-developed test for age-related macular degeneration in the U.S. Item

> Illumina ($ILMN) unveiled a new system that it says can produce full human DNA sequencing at $1,000 per genome. Story

Biotech News

@FierceBiotech: Auspex's $76M IPO pitch tests the limits of biotech's window. Story | Follow @FierceBiotech

@JohnCFierce: ICYMI: Roche 's dealmakers at pRED will continue their global shopping spree in 2014. Piece | Follow @JohnCFierce

@DamianFierce: Welcome back, Ariad: Iclusig returns after a cold winter. More | Follow @DamianFierce

@EmilyMFierce: Experimental microparticle therapy could treat inflammatory conditions, from effects of heart attack to diabetes. Article | Follow @EmilyMFierce

> Prosensa heralds new hope for once-failed muscular dystrophy drug. More

> Shire takes an L on Dermagraft, unloads it to Organogenesis. Story

> ArQule rides high on good news for its never-say-die cancer drug. News

Pharma News

@FiercePharma: Big Pharma accused of hatching 'satanic plot' in South Africa. More | Follow @FiercePharma

@TracyStaton: Trending at FiercePharma: Novartis may finally face generic competition for Diovan. Yesterday's story | Follow @TracyStaton

@EricPFierce: FDA investigator assigned to Europol to fight fakes being hawked online by drug rings. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Look for Teva's new chief to move fast on dealmaking, CFO says. Story | Follow @CarlyHFierce

> FDA advisory panel gives J&J's Xarelto resounding 'no' for ACS. Story

> Roche resolves shortage of liquid Tamiflu. Article

> Gilead's Sovaldi rolls on with approval in EU. Item

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.